Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer.

doi:10.1002/1878-0261.12108

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer.

Molecular oncology - 1 Oct 2017

Malgerud Linnéa, Lindberg Johan, Wirta Valtteri, Gustafsson-Liljefors Maria, Karimi Masoud, Moro Carlos Fernández, Stecker Katrin, Picker Alexander, Huelsewig Carolin, Stein Martin, Bohnert Regina, Del Chiaro Marco, Haas Stephan L, Heuchel Rainer L, Permert Johan, Maeurer Markus J, Brock Stephan, Verbeke Caroline S, Engstrand Lars, Jackson David B, Grönberg Henrik, Löhr Johannes Matthias

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) is a tumor with an extremely poor prognosis, predominantly as a result of chemotherapy resistance and numerous somatic mutations. Consequently, PDAC is a prime candidate for the use of sequencing to identify causative mutations, facilitating subsequent administration of targeted therapy. In a feasibility study, we retrospectively assessed the therapeutic recommendations of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Pancreatic Ductal

Share to Feasibility Studies

Share to Germ-Line Mutation

Share to Pancreatic Neoplasms

Share to Precision Medicine

Share to Proto-Oncogene Proteins p21(ras)

Share to Software

Source

Open in PubMed Open full text

Identifiers

PMID: 28675654
DOI: 10.1002/1878-0261.12108
PMCID: PMC5623817

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer.PMID 28675654Read ↗

Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017.Semantic proximity Read ↗

Building towards Precision Oncology for Pancreatic Cancer: Real-World Challenges and Opportunities.Semantic proximity Read ↗

Precision Medicine in Pancreatic Ductal Adenocarcinoma: The Impact of Targeted Therapies on Survival of Patients Harboring Actionable MutationsSemantic proximity Read ↗

TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 Trial.Semantic proximity Read ↗

Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial.Semantic proximity Read ↗

Applying next-generation sequencing to pancreatic cancer treatmentSemantic proximity Read ↗

A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinomaSemantic proximity Read ↗

Targeted next generation sequencing of endoscopic ultrasound acquired cytology from ampullary and pancreatic adenocarcinoma has the potential to aid patient stratification for optimal therapy selection.Semantic proximity Read ↗

FoundationOne® CDx gene profiling in Japanese pancreatic ductal adenocarcinoma patients: a single-institution experience.Semantic proximity Read ↗

CT Radiomics and Whole Genome Sequencing in Patients with Pancreatic Ductal Adenocarcinoma: Predictive Radiogenomics ModelingSemantic proximity Read ↗

A Predictive Noninvasive Single-Nucleotide Variation-Based Biomarker Signature for Resectable Pancreatic Cancer: Protocol for a Prospective Validation Study.Semantic proximity Read ↗

Next-generation sequencing and histological response assessment in peritoneal metastasis from pancreatic cancer treated with PIPAC.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.